Bajaj Healthcare Limited has made a regulatory disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

Key Quantitative Figures

The Nomination & Remuneration Committee, at its meeting held on July 20, 2026, approved the grant of 275 (Two Hundred Seventy-Five) stock options.

Each ESOP has an exercise price of ₹5 and is convertible into one fully paid-up equity share of face value ₹5 each.

The total number of equity shares covered by these options is 275.

The annexure states 2500 options are vested, though this appears inconsistent with the main grant of 275 options.

Significant Terms and Conditions

Eligibility: The scheme is open to:

  • Employees designated by the company working in India or outside India
  • Directors of the company (Whole-Time or Non-Executive) excluding independent directors
  • Employees of Group Companies including Subsidiary Companies or Associate Companies

Exclusions:

  • Promoters or members of the Promoter Group
  • Directors holding more than 10% of issued and subscribed shares (directly or through relatives/body corporate)
  • Independent Directors

Vesting Requirements:

  • Stock options vest within a maximum period of 4 years from the date of grant
  • Minimum period of one year between grant and vesting of stock options

Exercise Period:

All vested options may be exercised within 5 (Five) years from the date of vesting.

Lock-in Period:

Shares arising from exercised options are not subject to any lock-in period, except for restrictions under the company's Insider Trading Code.

Mode of Implementation:

The scheme is implemented directly by the company through the Board/Nomination and Remuneration Committee.

Current Status

  • Options exercised: Not applicable at this stage
  • Money realized by exercise of options: Not applicable at this stage
  • Total number of shares from exercised options: Not applicable at this stage
  • Options lapsed: Not applicable at this stage
  • Variation of terms: Not applicable at this stage
  • Diluted earnings per share impact: Not applicable at this stage

Financial Impact

The disclosure does not quantify any immediate financial impact. The potential dilution from the grant of 275 options would be minimal relative to the company's total share capital.